Iseganan
Also known as: IB-367, Iseganan HCl, Protegrin analogue IB-367
Source Iseganan at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Iseganan (IB-367) is a synthetic protegrin-derived antimicrobial peptide developed by InNexus/Intrabiotics Pharmaceuticals for prevention of oral mucositis and ventilator-associated pneumonia. Clinical trials failed to demonstrate efficacy over placebo, and development was discontinued. It retains interest as a research prototype for membrane-disrupting antimicrobials.
Mechanism of Action
Iseganan is a synthetic analogue of porcine protegrin-1, a beta-sheet antimicrobial peptide. It disrupts bacterial and fungal cell membranes by forming ion channels and causing membrane permeabilization, leading to rapid cell death. It acts broadly against gram-positive, gram-negative bacteria, and fungi.
Routes of Administration
Goals & Uses
- Prevention of oral mucositisOncology Supportive CareLow
- Broad-spectrum antimicrobial activityAntimicrobial ResearchModerate
- Prevention of ventilator-associated pneumoniaInfectious DiseaseLow
Contraindications
- Hypersensitivity to iseganan or protegrin analoguesAllergyHigh
Adverse Effects
- Altered tasteSensoryUncommon
- Mucosal irritationLocal ReactionUncommon
- Oral discomfort/burningLocal ReactionCommon
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNever received EMA marketing authorization.
- United StatesUnapprovedFailed Phase III trials; no NDA filed or approved by FDA.
- United KingdomUnapprovedNot approved by MHRA.
Iseganan did not receive regulatory approval in any jurisdiction. Phase III trials for oral mucositis in cancer patients and for ventilator-associated pneumonia were discontinued after failure to meet primary endpoints. No approved indications exist.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Iseganan?
Iseganan (IB-367) is a synthetic protegrin-derived antimicrobial peptide developed by InNexus/Intrabiotics Pharmaceuticals for prevention of oral mucositis and ventilator-associated pneumonia. Clinical trials failed to demonstrate efficacy over placebo, and development was discontinued. It retains interest as a research prototype for membrane-disrupting antimicrobials.
What is Iseganan used for?
Iseganan is educationally associated with: Prevention of oral mucositis, Broad-spectrum antimicrobial activity, Prevention of ventilator-associated pneumonia. Educational only — not medical advice.
How is Iseganan administered?
Recorded routes of administration: Inhalation, Oral Rinse, Topical.
What are the potential side effects of Iseganan?
Reported adverse effects include: Altered taste, Mucosal irritation, Oral discomfort/burning. This list is not exhaustive — consult a qualified clinician.
Who should avoid Iseganan?
Recorded contraindications: Hypersensitivity to iseganan or protegrin analogues. Consult a qualified clinician before use.